Imperial: First-in-class drug candidate for multiple myeloma shows promise in Phase 1 trial
- Feb 23
- 1 min read
A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.
Multiple myeloma (MM) is a cancer of plasma cells, accounting for about 200,000 annual new cases globally. Despite recent therapeutic advances, MM remains incurable and an area of substantial unmet medical need.
Professor Guido Franzoso in Imperial College London’s Department of Immunology and Inflammation said: “Almost all patients with multiple myeloma eventually relapse and develop resistance. We urgently need new therapies that can be combined with other drugs to provide durable control of the disease.”
